“I see—but not by sight alone” – a discussion of FDA’s final guidance, Recommended Acceptable Intake Limits for Nitrosamine Drug […]

Summary of the FDA, UMD Meeting on June 15, 2023, regarding “Mitigation Strategies for NDSRIs: Quality and BE Considerations” Aloka […]

Click Here to Register for Free Join SAAMnow for our 2023 series of webinars on 505(b)(2) NDA drug development starting April […]